Bayer Bolsters Nucleic Acid Diagnostics Portfolio With VGI Acquisition

Bayer Diagnostics will gain the only FDA-approved HIV sequencing resistance test available in the U.S. through its roughly $60 mil. cash acquisition of Visible Genetics, Inc